If we look at the human clinical studies for emerging monoclonal antibodies in treating asthma for the past 20 years, studies targeting IgE, IL-2, IL4R-alpha, IL-5, and IL-13 showed some efficacy, however those targeting TNF-alpha, TSLP and IL-9 did not show convincing effectiveness [38] and no asthma clinical trials targeting IL-6 have been conducted to the best of our knowledge. The gene discussed is TSLP; the disease is asthma.